These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

147 related articles for article (PubMed ID: 11911727)

  • 41. Are rofecoxib and celecoxib safer NSAIDS?
    Drug Ther Bull; 2000 Nov; 38(11):81-6. PubMed ID: 11138599
    [TBL] [Abstract][Full Text] [Related]  

  • 42. [Cox-2 inhibitors in the focus. Rofecoxib as effective as the "classics"].
    MMW Fortschr Med; 2001 Nov; 143(46):50-1. PubMed ID: 11759601
    [No Abstract]   [Full Text] [Related]  

  • 43. Rofecoxib-associated upper gastrointestinal bleed: a case report.
    Freedman GM; Kreitzer JM; Badola R
    Mt Sinai J Med; 2002; 69(1-2):105-6. PubMed ID: 11832981
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Efficacy and safety of rofecoxib in patients with chronic low back pain: results from two 4-week, randomized, placebo-controlled, parallel-group, double-blind trials.
    Katz N; Ju WD; Krupa DA; Sperling RS; Bozalis Rodgers D; Gertz BJ; Gimbel J; Coleman S; Fisher C; Nabizadeh S; Borenstein D;
    Spine (Phila Pa 1976); 2003 May; 28(9):851-8; discussion 859. PubMed ID: 12941996
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Aseptic meningitis possibly associated with celecoxib.
    Papaioannides DH; Korantzopoulos PG; Giotis CH
    Ann Pharmacother; 2004 Jan; 38(1):172. PubMed ID: 14742817
    [No Abstract]   [Full Text] [Related]  

  • 46. Rofecoxib: new preparation. A disappointing NSAID analgesic.
    Prescrire Int; 2000 Dec; 9(50):166-7, 169. PubMed ID: 11475491
    [TBL] [Abstract][Full Text] [Related]  

  • 47. [Prescribing patterns of rofecoxib in the primary care setting: results of a French survey].
    Bannwarth B; Logeart I; Vergult G
    Rev Med Interne; 2004 Oct; 25(10):710-4. PubMed ID: 15471596
    [TBL] [Abstract][Full Text] [Related]  

  • 48. [Is there a future for COX-2 inhibitors?].
    Yodfat Y
    Harefuah; 2004 Nov; 143(11):820-4, 837. PubMed ID: 15603272
    [TBL] [Abstract][Full Text] [Related]  

  • 49. [Drug-induced aseptic meningitis].
    Farr KP; Mogensen CB
    Ugeskr Laeger; 2010 Jan; 172(4):298-9. PubMed ID: 20105400
    [TBL] [Abstract][Full Text] [Related]  

  • 50. The cost-effectiveness of cyclooxygenase-2 selective inhibitors in the management of chronic arthritis.
    Spiegel BM; Targownik L; Dulai GS; Gralnek IM
    Ann Intern Med; 2003 May; 138(10):795-806. PubMed ID: 12755551
    [TBL] [Abstract][Full Text] [Related]  

  • 51. [New nonsteroidal antiinflammatory drugs in rheumatoid arthritis].
    Berenbaum F
    Ann Med Interne (Paris); 2002 Feb; 153(1):25-33. PubMed ID: 11994687
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Spontaneous reports of hypertension leading to hospitalisation in association with rofecoxib, celecoxib, nabumetone and oxaprozin.
    Brinker A; Goldkind L; Bonnel R; Beitz J
    Drugs Aging; 2004; 21(7):479-84. PubMed ID: 15132714
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Rofecoxib-induced pseudoporphyria.
    Markus R; Reddick ME; Rubenstein MC
    J Am Acad Dermatol; 2004 Apr; 50(4):647-8. PubMed ID: 15034522
    [No Abstract]   [Full Text] [Related]  

  • 54. What have we learned from the large outcomes trials of COX-2 selective inhibitors? The rheumatologist's perspective.
    Hochberg MC
    Clin Exp Rheumatol; 2001; 19(6 Suppl 25):S15-22. PubMed ID: 11695246
    [TBL] [Abstract][Full Text] [Related]  

  • 55. [The medical reason for the prescription of COX-2 selective cyclo oxygenase inhibitor rofecoxib for the treatment of rheumatoid arthritis. A post-marketing surveillance study from Austria].
    Lüth P; Herold M; Mur E
    Wien Med Wochenschr; 2005 May; 155(9-10):211-6. PubMed ID: 15999628
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Rofecoxib safe in NSAID hypersensitivity.
    Berges-Gimeno MP; Camacho-Garrido E; García-Rodriguez RM; Alfaya T; Martín García C; Hinojosa M
    Allergy; 2001 Oct; 56(10):1017-8. PubMed ID: 11576089
    [No Abstract]   [Full Text] [Related]  

  • 57. New use approved for Vioxx.
    FDA Consum; 2002; 36(4):3. PubMed ID: 12184302
    [No Abstract]   [Full Text] [Related]  

  • 58. Central retinal vein occlusion in a patient with rheumatoid arthritis taking rofecoxib.
    Meyer Ch; Gähler R
    Lancet; 2002 Oct; 360(9339):1100. PubMed ID: 12384019
    [No Abstract]   [Full Text] [Related]  

  • 59. Is rofecoxib safer than naproxen?
    Adelman A
    J Fam Pract; 2001 Mar; 50(3):204. PubMed ID: 11252204
    [No Abstract]   [Full Text] [Related]  

  • 60. Selective COX-2 inhibition and cardiovascular effects: a review of the rofecoxib development program.
    Weir MR; Sperling RS; Reicin A; Gertz BJ
    Am Heart J; 2003 Oct; 146(4):591-604. PubMed ID: 14564311
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.